Study on Chemo-Immunotherapy and Surgery for Advanced Non-Small Cell Lung Cancer with Lymph Node Involvement

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of stage 3 B/C non-small cell lung cancer (NSCLC) with specific lymph node involvement.
• The primary lung tumor must be suitable for surgery with the goal of curing the cancer.
• Must not have any major health issues that would make surgery too risky.
• Must have good lung function to tolerate the planned lung surgery.
• Must have specific genetic markers (EGFR, ALK) unless the cancer is a certain type (pure squamous NSCLC).
• Must be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have adequate blood counts and organ function based on specific lab tests.
• Women of childbearing potential must agree to use effective contraception during the study and for four months after the last treatment.
• Men must agree to use effective contraception and not donate sperm during the study and for four months after the last treatment.

Exclusion Criteria

• Have a type of lung cancer that is not suitable for this study, such as large cell neuroendocrine carcinoma or small cell lung cancer.
• The primary lung tumor is not suitable for surgery.
• Have received any prior treatment for the current lung cancer.
• Have had another cancer requiring treatment within the last two years, except for certain low-risk cancers.
• Have a history of significant autoimmune disease that could be worsened by immunotherapy, with some exceptions for well-controlled conditions.
• Have certain lung diseases or active lung inflammation.
• Have active tuberculosis.
• Have poorly controlled HIV, unless stable on treatment with undetectable viral load and adequate CD4 count.
• Have poorly controlled hepatitis B or C, unless the infection is well-managed.
• Have had a severe infection recently that could affect safety.
• Have had a stem cell or organ transplant.
• Have received a live vaccine recently or plan to during the study.
• Have significant heart or blood vessel disease recently.
• Are taking certain immunosuppressive medications, with some exceptions for low-dose or specific types of steroids.
• Have used immune checkpoint inhibitors before.
• Have severe allergies to study drugs.
• Are pregnant, breastfeeding, or planning to become pregnant during the study or within six months after the last treatment.